<SEC-DOCUMENT>0001776985-24-000057.txt : 20240624
<SEC-HEADER>0001776985-24-000057.hdr.sgml : 20240624
<ACCEPTANCE-DATETIME>20240624080743
ACCESSION NUMBER:		0001776985-24-000057
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240624
FILED AS OF DATE:		20240624
DATE AS OF CHANGE:		20240624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		241062154

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190840

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kbnt324fasttrack24ju.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib6657d74be33404f8f6175e4d31e9a23_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF JUNE 2024</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:106%">On June </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:106%">24,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:106%"> 2024, BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration granted Fast Track designation for BNT324&#47;DB-1311 for the treatment of patients with advanced&#47;unresectable, or metastatic castration&#8211;resistant prostate cancer who have progressed on or after standard systemic regimens. The press release is attached hereto as Exhibit 99.1.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Jens Holstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Jens Holstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; June </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24, 2024</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="ex991bnt324fast-track24jun.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324&#47;DB-1311 in Prostate Cancer</a></font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991bnt324fast-track24jun.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3a8be2da1992406396768041357058be_1"></div><div style="min-height:99.36pt;width:100%"><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div style="padding-left:360pt;text-indent:36pt"><font><br></font></div><div style="padding-left:360pt;text-indent:36pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:125%">BioNTech and DualityBio Receive FDA Fast Track Designation <br>for Antibody-Drug Conjugate Candidate BNT324&#47;DB-1311 <br>in Prostate Cancer </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">Designation is based on</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">pre-clinical data and data from an ongoing Phase 1&#47;2 trial for BNT324&#47;DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1&#47;2 clinical data</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">from patients with advanced or metastatic solid tumors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">i,ii</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">With the Fast Track designation,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">the development of BNT324&#47;DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) to support development and expedite regulatory review</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">Prostate cancer is the second leading cause of cancer-related deaths among men worldwide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">iii</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%"> often diagnosed at advanced disease stages&#59; patients with metastatic castration&#8211;resistant prostate cancer (&#8220;mCRPC&#8221;), an advanced form of prostate cancer, have a 5-year survival rate of around 36%</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">iv</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%;padding-left:14.5pt">All three clinical stage antibody-drug conjugate (&#8220;ADC&#8221;) candidates in BioNTech&#8217;s and DualityBio&#8217;s strategic collaboration have received FDA Fast Track designation supporting the potential of the companies&#8217; ADC technology</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">MAINZ, Germany and SHANGHAI, China, June 24, 2024&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8211;&#160;BioNTech SE&#160;(Nasdaq&#58; BNTX, &#8220;BioNTech&#8221;) and Duality Biologics (Suzhou) Co., Ltd. (&#8220;DualityBio&#8221;) today announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for BNT324&#47;DB-1311 for the treatment of patients with advanced&#47;unresectable, or metastatic castration-resistant prostate cancer (&#8220;CRPC&#8221;) who have progressed on or after standard systemic regimens. BNT324&#47;DB-1311 is a next-generation antibody-drug conjugate (&#8220;ADC&#8221;) candidate targeting the transmembrane glycoprotein B7-H3, an immune checkpoint protein which is overexpressed in a range of tumor types and has been associated with disease progression and poor prognosis for patients. The candidate is currently being evaluated in an ongoing Phase 1&#47;2 study (NCT05914116) in patients with advanced solid tumors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;The FDA&#8217;s decision is a recognition of the potential of our B7-H3-targeting ADC candidate for the treatment of advanced CRPC. While patients with metastatic prostate cancer initially respond to hormone therapy, most patients progress after 18-24 months and develop CRPC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">an advanced form of prostate cancer, leading to a poor prognosis for these patients. The 5-year survival rate for patients with metastatic CRPC is only around 36%,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prof. &#214;zlem T&#252;reci, M.D., Chief Medical Officer and Co-Founder at BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. &#8220;We are committed to further advancing BNT324&#47;DB-1311 with our partner DualityBio and believe that a targeted ADC immunotherapy approach has the potential to improve outcomes for patients at advanced stages of the disease.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;BNT324&#47;DB-1311 is the third asset in our strategic collaboration which has received FDA Fast Track designation,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">highlighting the potential of the candidate to fill an unmet medical need for novel treatment options for B7-H3 expressing cancers,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Vivian Gu, M.D., Chief Medical Officer at DualityBio</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. &#8220;Preliminary data from our ongoing Phase 1&#47;2 trial has demonstrated antitumor activity and a manageable safety profile of BNT324&#47;DB-1311 in patients with advanced solid tumors. With the designation and support by the FDA, we seek to expedite further development of BNT324&#47;DB-1311.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines that are intended to treat or prevent serious conditions and have the potential to address an unmet medical need. The designation is based on preliminary safety and efficacy data from an ongoing Phase 1&#47;2 trial with BNT324&#47;DB-1311 in patients advanced or metastatic solid tumors. With the Fast Track designation, the development of BNT324&#47;DB-1311 can benefit from more frequent engagement with the FDA, to support the development and expedite the regulatory review of BNT324&#47;DB-1311. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All three clinical stage ADC candidates in BioNTech&#8217;s and DualityBio&#8217;s global strategic partnership have received FDA Fast Track designation. The lead candidate in the collaboration, BNT323&#47;DB-1303, a next-ADC candidate targeting the Human Epidermal Growth Factor Receptor 2 (&#8220;HER2&#8221;), is being evaluated in a  Phase 1&#47;2 trial in patients with advanced solid tumors and a global Phase 3 clinical trial in patients with metastatic breast cancer.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The BNT323&#47;DB-1303 program received the Fast Track designation and Breakthrough Therapy designation from the FDA for the treatment of endometrial cancer in 2023. In January 2024, the companies&#8217; ADC candidate targeting the trophoblast cell-surface antigen 2 (&#8220;TROP2&#8221;), BNT325&#47;DB-1305</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> received FDA Fast Track designation for the treatment of patients with platinum-resistant ovarian epithelial cancer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About BNT324&#47;DB-1311</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BNT324&#47;DB-1311 is a next-generation topoisomerase-I-inhibitor-based ADC candidate targeting the immune checkpoint protein B7-H3. The transmembrane glycoprotein B7-H3 plays a critical role in the anti-tumor immune response and the shaping of the tumor microenvironment. It is overexpressed in a range of solid tumors, with limited expression in healthy tissues, and has been associated with disease progression and very poor prognosis.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">v</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Preclinical studies have shown that BNT324&#47;DB-1311 exhibits antitumor activity in various solid tumor models.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> Preliminary data from the ongoing Phase 1&#47;2 trial has demonstrated antitumor activity and a manageable safety profile for BNT324&#47;DB-1311 in patients with advanced solid tumors.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> BNT324&#47;DB-1311 is currently being evaluated in a Phase 1&#47;2 clinical trial (NCT05914116) in patients with advanced or metastatic solid tumors. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About BioNTech</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (&#8220;CAR&#8221;) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (&#8220;ADC&#8221;) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Biotheus, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For more information, please visit&#160;www.BioNTech.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">About DualityBio</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced four assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing to evolve its novel protein engineering and ADC technology platforms for the next wave of &#8220;super ADC&#8221; molecules including diverse payload classes, bispecific ADCs and dual payload ADCs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For more information, please visit&#160;www.dualitybiologics.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">BioNTech Forward-Looking Statements</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not be limited to, statements concerning&#58; the collaboration between BioNTech and DualityBio to jointly clinically develop antibody-drug conjugates (ADCs), including BNT324&#47;DB-1311&#59; the registrational potential of any trial we may initiate for BNT324&#47;DB-1311&#59; the nature and characterization of and timing for release of clinical data across BioNTech&#8217;s platforms, which is subject to peer review, regulatory review and market interpretation&#59; the planned next steps in BioNTech&#8217;s pipeline programs, including, but not limited to, statements regarding timing or plans for initiation or enrollment of clinical trials, or submission for and receipt of product approvals and potential commercialization with respect to BioNTech&#8217;s product candidates&#59; the ability of BioNTech&#8217;s mRNA technology to demonstrate clinical efficacy outside of BioNTech&#8217;s infectious disease platform&#59; and the potential safety and efficacy of BioNTech&#8217;s product candidates. In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The forward-looking statements in this press release are based on BioNTech&#8217;s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech&#8217;s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data&#59; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation&#59; the ability to produce comparable clinical results in future clinical trials&#59; the timing of and BioNTech&#8217;s ability to obtain and maintain regulatory approval for its product candidates&#59; discussions with regulatory agencies regarding timing and requirements for additional clinical trials&#59; BioNTech&#8217;s and its counterparties&#8217; ability to manage and source necessary energy resources&#59; BioNTech&#8217;s ability to identify research opportunities and discover and develop investigational medicines&#59; the ability and willingness of BioNTech&#8217;s third-party collaborators to continue research and development activities relating to BioNTech&#8217;s development candidates and investigational medicines&#59; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech&#59; BioNTech&#8217;s and its collaborators&#8217; ability to commercialize and market, if approved, its product candidates&#59; BioNTech&#8217;s ability to manage its development and expansion&#59; regulatory developments in the United States and other countries&#59; BioNTech&#8217;s ability to effectively scale its production capabilities and manufacture its products and product candidates&#59; risks relating to the global financial system and markets&#59; and other factors not known to BioNTech at this time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">You should review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in BioNTech's Report on Form 6-K for the period ended March 31, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC&#8217;s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CONTACTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">BioNTech</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div><img alt="image_1.jpg" src="image_1.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Investor Relations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><br>Victoria Meissner, M.D.<br>+1 617 528 8293<br>Investors&#64;biontech.de</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Media Relations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><br>Jasmina Alatovic<br>+49 (0)6131 9084 1513<br>Media&#64;biontech.de </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">DualityBio</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><br>Business Development<br>bd&#64;dualitybiologics.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:124%;position:relative;top:-3.5pt;vertical-align:baseline">i</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%"> Data on file.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:124%;position:relative;top:-3.5pt;vertical-align:baseline">ii</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%"> Li C, Yao J, et al. Cancer Res (2023) 83 (7_Supplement)&#58; 2967.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:124%;position:relative;top:-3.5pt;vertical-align:baseline">iii</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%"> Cancer TODAY. Global Cancer Statistics 2020&#58; GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Available at&#58; https&#58;&#47;&#47;gco.iarc.who.int (last access&#58; 20.06.2024).</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:124%;position:relative;top:-3.5pt;vertical-align:baseline">iv</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%"> SEER*Explorer&#58; An interactive website for SEER cancer statistics. Cancer Stat Facts&#58; Prostate Cancer. 2024 Apr 17.Available at&#58; https&#58;&#47;&#47;seer.cancer.gov&#47;statfacts&#47;html&#47;prost.html (last access&#58; 20.06.2024).</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:124%;position:relative;top:-3.5pt;vertical-align:baseline">v</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%"> Ranjana K. Kanchan, et al. Biochim Biophys Acta Rev Cancer. 2022 Sep&#59;1877(5)&#58;188783.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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MOLEKTI^/#O'^+A_'C51K'O?'@;R; 319;'_1>L")?HPDJ>^M0#$UW:U1&G_
M=$BJ*@ON"M$6P%'  U$:GQRE\6:F1)*D,(T.\7:*J4%:<5WZR]$A=N[6L0P,
M\SQ4:B'/BP>&F=7%MM^3YHOM+WIO.0>\)$FK [^.TOB"*(U?;3HD58T%=X5L
M$8HYWZ^,TOCJ*(T_&:7QPJ9%DJ2@?*.%VUH(^,WH$-MV\7C^6*'<G].M'8\.
ML1OPTQ9O]@ _3I*DV6P+W%@^ 3_!=$BJ"@ONJHHW4CQJ?&^4QH,NIB))4O>-
M#O%*8/L6;W8A(!L=XLU=.JQ?0/=&C8_#\\#ONM3N,7!J&^XEWC0ZQ 9^LB1)
MLUF"X@GX+$KC%4V'I"JPX*ZJ61GX(7!/E,8'1FF\K"F1)*EKMFG3=A<#SAT=
M8I-.']# , ]0C5'NOQP8YNE.[[1\^N ,BA]&VF%;/U:2I#G8$;@A2F//$Y*"
M9\%=5;4\<!!%X7W(5<PE2>J*U[1QVTL#YXT.L4X7CNL[@>=]%O#]3N]T=(C-
M*4;5M_.Z:ST_5I*DN5@%.#]*XWU,A:2067!7U2T#' [<$:7QIZ(TMD]+DM0Y
MR[9Y^RL %XP.L7HG#VI@F,N /P><]U\,#'-K)W<X.L2&0$;Q0T@[.8A"DC0O
M"P!'1VE\=)3&$TV'I%"_J*1>L!K%PEW_C-+X[:9#DJ2.>+0#^UB5HNC^B@X?
MV[[ "P'F_&G@JYW<X>@0:P-_HO@!I-V>\V,E21J#?8#?1&F\L*F0%!H+[NHU
MKP,NBM+X9U$:KV0Z)$EJJYL[M)^U@+^,#K%<IPYL8)B[@&\&F/,O#@SS4*=V
M-CK$:L"Y%#]\=,(M?JPD26.T*T71?5%3(2DD%MS5JW8';H_2>&^GF9$DJ6TN
M J9T:%\;4"RDND0'C^^'P#D!Y?O4@6%.[M3.1H=8D:+8OE8'C_$\/U:2I''8
M"3C;D>Z20F(A4KUL6> 8X((HC5<W'9(DM=; ,$\!IW5PEYL!YXP.L7"'CF\6
M\#'@F@#2_3?@,YW:V>@0RP!_H'AZL%,N'!CF3C]9DJ1Q>B=P<I3&$TR%I!!8
M<%<_V!JX,4KC3YH*29):[B#@F0[N;QO@-QTLNC\#O!NXJ8LY_@>PT\ PSW=B
M9Z-#+ Z<#6S:P6.<"0SY<9(D->@CP(AID!2"!4V!^L12P(E1&N\*?"9/LD=-
MB21)S1L8YO[1(?8!3NG@;G<"?CXZQ,<&AIG1@6-\;'2(+2FFE]FJPRG^"_#>
M@6&>[<3.RA\R?@]T>A'Z0P>&N=I/E"2I"?M%:7Q3GF0_[;4#*T?OOQ[8 E@'
M6!T8 )8 )E,,?K@/N)WBA_JK\B2;;I>0NL."N_K-SL"F41I_)$^RBTV')$G-
M&QCFU-$A7@,<T,'=?@B8.CK$'N74+^T^QJ=&AW@'\%W@2QTZQF'@FP/#=.2&
MN2RV_P9X1X>[T*D43TI(DM2LGY1%]RNK?B!ED?UMP,<I%HA=81QO?RY*XS\
M/P/.L_@N=993RJ@?K0)<&*7Q-YSC39*DUA@8YD"* G$G?0+XR>@0$SITC-,&
MAODRL#W%"+)VN1W8=F"8_3M8;)\(G$SQ]$ GG0;LV8D?321)?6%AX+=1&B]?
MU0.(TGA"E,8?!*ZE6*!^+\97;(=BY/MN%.NQW!:E\9Y1&COH5NH0/VSJ5PL
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MRY/LY&[M/$KC)8"5@ A8$U@+> WP.F =^JLF]"I@+^#' <2R/[!&8/E9!3B
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ML"/P=!=V_VW@=Z-#O?-DW^@0 T!&=XKMDX$=!X:YW9XM23U7(W@^3[)3@#<
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M$^[T1'M$:>Q]['\=&&A<Y^9)]G>;1RWT/' (L&&>9.>;CKZ_]_LV#K3J1RL
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M]:M5*A"C!7?UM2B-%P#BP,,\+$\RIW*8OR$LN"M\59X6RN\A=>OF>C1*X].
M3P<6VD>C-/Y2GF0O5#"M^Q+FZ/9OV.,;\GB>9/<$$LLM\[CNG@B\BF*ZE0V!
M3<K7>O1VW>CCP'7 B%VUX_=Z"P.?#?D4![S7.=O'[:O :P.^CU\2V ,XJMT[
M<DH9]:LJ%-R=PUW];A-@(.#X'@)^9#.-X6HUR:X#?FTF%+*!81X%IE4T?->0
M4#?].,"8EJ,:B_"]1#FZ_<L!AO;[/,FNL*OW]+7:C#S)[LF3[((\R8[(DVR/
M/,E>#RQ+L9[2$<RC8%]QPU$:;VDOZ+CW43QQ$:(7*!9(?<1F&O]W"?!1X*Z
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MV8J!GIMNRY-LALW3TANMR<"]9D(!JM*H\4=L+@7NR,#B60+X8+=V7@XL."#
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MIL:4 P]#&ORW / 16Z;C]X$; QL$%M;U[>I@4I4<!;RMHK&?D2?9+0'$\6!
M.5FQ++RI,:\(*):'RC4"6G(]%FB^+;BWSNN!%4R# N>4,E('E87BHP,)9YMR
MH,^\B@;K .\.*(57YDEVECU)553>$U;A/O]A6ZLI5P46SV>B-'9=N0[G/,"8
MKFS'1BUTJ4HGX0. I*+ASP(."226D$:X+X"CW)NQ2D"QM/*'G'\'FN\WV^5:
MYIVF0!40<E';$>[J52<"4P*(8TGF_T/[%P/+W3?L/JJPC8"!"L29VU1-N22P
M>-8#MK%9.B-*XZ6!W0.\IG9*&?7U!_-SP,$5/H1?!#*Z'>"^P'+CO&F-"^G'
MBE9>?-X::+ZW<@1$R\2F0!7@E#)2IR\FDFP4.#64\_X\[DV6"ZQH<'&>9!?8
M@U1A[ZM(G/?:5$VY*,"8OFRS=,QG*'[0#LFE>9+-:,>&+;@K>%$:[P[\I,*'
M,(VP?BRX/[#\K&HO;^ASL0#PJI#ND5NXK5 +[BL &]K[FNZ[*P%O-1.J  ON
M4G>$LGCJ5O/X;WL!2P24L_WM-JJX#U8DSG_;5$VY&G@NL)C>':7Q)C9-V^\!
M%R/,'S?:]M2%!7>%_J'<&SBIXH?QDSS)[@HHGKL"R\^Z]O2&K $L$E \=[1P
M6WF %V+_N2"SZS7M UY_J")"+FI/LGG4J_(D^R=A3#OPUCD]V1:E\8+ O@&E
M+,N3[ I[CBI\S_\68)V*A'NK+=;4]_MT(,2G<0ZV==KNLX0YN\&Y[=JP-[P*
M^<3[1>"8BO?3280S=_N+)[D'@,D!A;2!O;TG\G9W"_OH+."60/.^DUVO:9\P
M!:J(9P*.S453U>N.#""& 6#M.?S[78$HH%P=8'=1Q55IG;:;;*ZF92'>XT5I
MO)5-TQY1&B\+?#/ T.[+D^SZ=FW<@KM"_#!.B-+X4."('CB< \NY*$,3TBCW
M]>WU/9&WNUN\O6L#S?M;HC1^I=VOX>_W]8$MS(0JPBEEI.XYFS#6'=IL#O_N
M<P'EZ5=YDEUG=U&%KPTCX*,5"??A0._MJR8#9@48UQ%1&D^T>=KB &#Y .,Z
MIYT;M^"NT$ZXBP.G ]_H@</Y)^'./1]4P=V%*!ORNH!B>;X--\57!YKW"113
MHJ@Q^Y@"5<BS <=FP5T]K9QVX-@ 0MGL9?<J:P/;!I*F&<"!]A95W!"P4$5B
M_8?-U9+O]X<"S>4;".L'U9X0I?%&P!<"#>_W[=RX!7>%]$%<A6+5ZMUZY)#^
MK[Q9"%%(C\(M!:SG)V#<-@THEIOS))O9XFU>%7#N/V7W:^@[?EE@#S.A"@EY
MVI;)-H_ZP/' "UV.X8TO^_\A37UQ:IYDM]M-5.%KPW6HUG0RKI70.J<'&M=W
MHC1>W>9IV6=\0>"G0(A/#CP&7-C.'5AP5R@?Q,TH?N7<M$<.Z<0\R?X><'S_
M#"R>+?T4C.OSL@)A+2QT0QNV>0LP)= FV"A*XS?:$\?M\\"2ID$5\GS L3UG
M\ZC7Y4GV&/#+ ,[Y$\KKKX6!/0-)SS2<NUW5-P(L6*%X+;BWSB^!F0'&M11P
MLD_@M\S7^=\?KD-Q>IYDT]JY PONZKHHC?<!_@ZLVB.'] CPI<!CO"&P>-[A
M)V%<M@TLGI;_@%,^'7)9P&WP!;OAN+[GEP*^:"94,2$7W)U21OWBJ"[O?TE@
MS?)_[PJL&$A>TCS)<KN'*GQM^#%@QPJ%_ (6W%MYK_<P\)= P]N:8JHC-?<9
MWY*P?Q@^M=T[L."N;GX EXW2^#3@:*HS;]M8[),GV:3 8_P788V.V\X%2L;E
M78'%TZX?<"X*N T^XN*IX_)5PEPH1YJ7D*>4F6+SJ!_D278-<'F7PWA]^<]0
MII1['CC,WJ$*UP$BX,<5"_NR/,F<SJVU3@XXMD.C--[:)FKX,[XBQ;1!H=9X
M;LN3K.U3V%IP5[<^@-M3S"/^D1X[M%_D2?;;"MR\S 2N#RBD 8I?DC7_S\Y$
M( XHI)G -6W:]D4!-\5"%$5DS;_/K@H,F@E5T L!QV;!7?WDR"[O?X,HC5<"
MM@\D'S\J%QV4JGA=N##P*V"YBH5^OJW7<F=2S*,=HHG &5$:KV$S-?09/Y.P
M9[#X22=V8L%=G?[PK1"E\?' >?3.%#(ONA_8MT+QAC9=QP?]A(S)-H3S.#,4
M"Z8^TZ9M7P4\&W!;?+9<[%GS5@<6-PVJFH'AH!<F?<H64A_Y+?!P%_>_#O"A
M0.Z=GP)^8)=0A1T+;%'!N/]@T[56GF13@33@$%<$SHG2>!E;:VS*N>^/ [8*
M.,QG@9]U8D<6W-6I#]X"41I_!K@-V*L'#W$FL$<%II*976AST.T6I?&B?EKF
M:X_ XFG;8][E1=A? FZ+1?&1[OE]][\;?TQ3M86Z.*DCW-4WRNN!8[L8PGK
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MCJ,8"=D/3Y0=T&/W'>J=Z[]E*::3^ RP:0\>XD5YDEUM2W?<0<!'J-83L^\
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M\K5TA;O'G_,DNS*@OGI'E,8_H1A]775K D< WRN+!F< Y^9)]DP'^^HK@ \
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M;!Q83'_*D^PRFT8:5^W@=."T/,G^83K4@?O!.X%W16F\<WGOO*Y9::GG@:.
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MZ-.4S 3^#/S4>L3<39@UJ[53KTZ8,,&L2AKOS=)RP <IBIE; 7Z1S-D#P*G
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MI&ZQX"Y)DB1)&I<HC7<&-@\LK"OS)/N]K2-)DKK)@KLD29(D:<RB-%X ."3
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M!CW6)A.:>.]3=FE563FETL>!KP+KM7%75P+O'JG7)Y?SPN\/? "8V.;/]I[
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M>%-@<>T)[-CD9@X8J=>GC^/OFUF8]8\-O,=!2I(D21HS"^Z2)$E2@ 9KM46
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M731N7KL<FZ8^A\P%#DW)(=])JR5LJX"[B(B(2 4IX)[^T#  N(FTG-=M'=^
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MTIK.HG@C(=5YT7UJG=MJ(;'%/Z3/JN,ZGA#,3@9^EK#OFRF^?!01$>GL>-J
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KB(B(B&2@@+N(B(B(B(B(B(B(2 ;_/P#2H5+R1MF\ P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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MK3\5>I4J1S[Y!NYNE<C !Y$LY308I18U7\8-\@U\/[Z!$\+M!R-Z<1/S1LO
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C",_E5ZCR0<?L6=E4'_A_L_A HG+[_HL     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
